GlassScriptPhysician profile
Amy Mosman
NPI 1255756961
$21,492.57
in general payments reported to CMS, 2019-2025
24 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.45 · 2022: $361 · 2023: $770 · 2024: $6,284 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,600 · Travel and Lodging: $5,701 · Food and Beverage: $4,646 · Consulting Fee: $3,115 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,600.00 |
| Travel and Lodging | $5,701.04 |
| Food and Beverage | $4,645.94 |
| Consulting Fee | $3,115.00 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $16,620.89 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Novo Nordisk INC | $1,449.13 | 2021-2025 | Ozempic |
| Medtronic, INC. | $1,050.93 | 2022-2024 | Ellipsys Vascular Access System |
| Amgen INC. | $390.31 | 2023-2024 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $245.56 | 2023-2025 | |
| Scpharmaceuticals INC. | $219.29 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $204.51 | 2022-2024 | Lokelma |
| Janssen Scientific Affairs, LLC | $158.54 | 2023 | Xarelto |
| Madrigal Pharmaceuticals | $129.20 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $125.00 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $121.52 | 2025 | Blujepa |
| Corcept Therapeutics | $106.13 | 2025 | Korlym |
| Vifor Pharma, INC. | $97.69 | 2022 | |
| Phathom Pharmaceuticals, INC. | $96.74 | 2024 | Voquezna |
| Convatec INC. | $95.50 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $92.31 | 2025 | |
| Abbvie INC. | $90.58 | 2025 | |
| Travere Therapeutics, INC. | $43.77 | 2024-2025 | |
| Cormedix INC. | $35.71 | 2024 | Defencath |
| Nxstage Medical, INC. | $34.29 | 2022 | |
| Akebia Therapeutics INC | $23.76 | 2024 | Auryxia |
| Calliditas Therapeutics US INC. | $22.33 | 2024 | |
| Fresenius USA Marketing, INC. | $20.03 | 2023 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Mosman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.